Rekha(Tripathi)ChaudharyMD

Oncology • West Chester, OH

Physician

Join to view full profile

Dr. Chaudhary is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chaudhary's full profile

Already have an account?

Office
7675 Wellness Way
Suite 201
West Chester, OH 45069
Phone+1 513-475-8500

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2001 - 2004
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1998 - 2001
Northeast Ohio Medical UniversityClass of 1998

Certifications & Licensure

OH State Medical License 1999 - 2025
VA State Medical License 2005 - 2008
MI State Medical License 2001 - 2005
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

197 citations
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Linda M Liau, Keyoumars Ashkan, David D Tran, Jian L Campian, John E Trusheim
Journal of Translational Medicine. 2018-05-29
4 citations
NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma.
Tracy T Batchelor, Minhee Won, Arnab Chakravarti, Costas G Hadjipanayis, Wenyin Shi
Neuro-Oncology Advances. 2023-10-11
3 citations
Factors associated with radiation necrosis and intracranial control in patients treated with immune checkpoint inhibitors and stereotactic radiotherapy.
Jacob Hall, Kevin Lui, Xianming Tan, John Shumway, Frances Collichio
Radiotherapy and Oncology. 2023-12-01

Press Mentions

Collaborative University of Cincinnati Cancer Center Team Opens Phase 2 Brain Tumor TrialMarch 27th, 2024